Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system-Reference-Cited by-同舟云学术

Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system

Published:2020-11 Issue:1 Volume:10 Page:87-97
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med.

Author:

Zhou Yuan¹²^ORCID,Lin Changming³,Hu Zhihua¹²,Yang Cheng⁴,Zhang Rentao¹²,Ding Yinman¹²,Wang Zhengquan¹²,Tao Sha¹²,Qin Yanmei⁵

Affiliation:

1. Department of Urology Surgery The People’s Hospital of Xuancheng City Xuancheng China

2. Wannan Medical College Yijiang China

3. Department of Urology Surgery The Fourth Affiliated Hospital of AnHui Medical University Hefei China

4. Department of Urology Surgery The First Affiliated Hospital of Anhui Medical University Hefei China

5. Shanghai Key Laboratory of Tuberculosis Clinic and Research Center of Tuberculosis Shanghai Pulmonary HospitalTongji University School of Medicine Shanghai China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3571

Reference26 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Cancer statistics, 2017

3. THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY

4. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging

5. How Well Does the Gleason Score Predict Prostate Cancer Death? A 20-Year Followup of a Population Based Cohort in Sweden

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. L’évolution donne souvent la solution;Annales de Pathologie;2024-08

2. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy;BJU International;2024-06-28

3. Prognosis of Gleason Score 9–10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study;European Urology Oncology;2023-11

4. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide;Cancer Chemotherapy and Pharmacology;2023-09-29

5. Nomogram for predicting the overall survival of patients with early‐onset prostate cancer: A population‐based retrospective study;Cancer Medicine;2022-03-23